WE ARE PHARMATHEN

Our History

Successful Milestones

1969

Establishment of Pharmathen by the pharmacist Nikolaos Katsos

1973

Commencement of manufacturing activities

1975

First in-house development

1993

Leadership passes to Vassilios Katsos and Nelly Katsou

1998

Strategic refocusing of business activities in order to target the international market

2002

Launch of Pharmathen’s first product in the E.U. (Fluconazole)

2006

Inauguration of API research facility in Thessaloniki — a step towards vertical integration

2010

Acquisition of a research facility for API synthesis in India

Global presence extends to 65 countries

Commencement of operations at our new manufacturing unit in Sapes, North Greece

2011

Initiation of new R&D activities focused on specialty products

2012

The Group exceeds the landmark of €150 million in turnover

Initiation of new commercial activities for pharmacies in Greece, representing renowned international brands

2013

First product launch and commencement of business activities in the United States

2014

First Greek Company to be financed by European Investment Bank

2015

Front runners in Long Acting Injectables (LAI) technologies and Preservative Free Ophthalmics

Acquisition of a majority stake of shares of the Group by the investment group BC Partners

2016

Incorporation of the Dutch parent company, Pharmathen Global BV, which shall assume the commercialization of all Group’s products to international customers

2017

Successful completion of our first Long-acting Injectable development

Successful completion of our first inspection by U.S Food & Drug Administration